MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3238/arztebl.2009.0843

Медицинская библиотека · Deutsches Arzteblatt international · 2009

Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases.

Schmiegel Wolff, Pox Christian, Arnold Dirk, Porschen Rainer, Rödel Claus, Reinacher-Schick Anke, Association of the Scientific Medical Societies in Germany, German Cancer Aid, German Cancer Society, German Society for Digestive and Metabolic Diseases, German Society for General and Visceral Surgery, German Society for Hematology and Oncology, German Society for Pathology, German Society for Radiooncology, German Roentgen Society, German Joint Society for Clinical Chemistry and Laboratory Medicine, German Society for Coloproctology, Association of Stoma Patients and Persons with Intestinal Cancer, German Crohn's Disease and Ulcerative Colitis Association, German Society for Internal Medicine

СтатьяКлинические рекомендацииПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Colorectal carcinoma (CRC) is the second most common type of cancer in Germany. In view of recent major changes in the diagnosis and treatment of CRC, the S3 guideline for CRC published in its full version in 2004 was partially updated in 2008 and again in 2009.

METHOD: The literature was systematically searched for all articles published from 2004 onward concerning polyp management, (neo-)adjuvant treatment, and treatment of metastatic disease. Evidence-based recommendations were developed in a consensus conference.

RESULTS

For some patients who have undergone polypectomy, the time to follow-up with colonoscopy can be lengthened. In UICC stage III colon cancer, adjuvant chemotherapy with an oxaliplatin-based regimen is recommended. In stage II colon cancer, adjuvant chemotherapy should be considered mainly when risk factors are present. In stages II and III, neo-adjuvant therapy should be given before resection in rectal cancer. In patients with metastatic disease, the use of all possible treatment options results in a median overall survival time of 24 months. In some patients with primarily non-resectable liver metastases, systemic treatment may enable a secondary, potentially curative resection. Therapeutic agents are chosen individually on the basis of clinical factors including the goal of treatment, the patient's general condition, and tumor molecular markers.

CONCLUSION

The S3 guideline contains evidence-based recommendations for the diagnosis and treatment of colorectal carcinoma. Broad implementation of the guideline will be essential for improved patient care.

Для цитирования: Schmiegel Wolff, Pox Christian, Arnold Dirk, Porschen Rainer, Rödel Claus, Reinacher-Schick Anke, Association of the Scientific Medical Societies in Germany, German Cancer Aid, German Cancer Society, German Society for Digestive and Metabolic Diseases, German Society for General and Visceral Surgery, German Society for Hematology and Oncology, German Society for Pathology, German Society for Radiooncology, German Roentgen Society, German Joint Society for Clinical Chemistry and Laboratory Medicine, German Society for Coloproctology, Association of Stoma Patients and Persons with Intestinal Cancer, German Crohn's Disease and Ulcerative Colitis Association, German Society for Internal Medicine. Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases.. Deutsches Arzteblatt international. 2009. DOI: 10.3238/arztebl.2009.0843.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.